Glaxosmithkline Share News (GSK)

Sarepta says FDA raises doubt about drug trial, shares drop 39 pct

Nov 12 (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had raised concerns about the trial for the company's experimental muscle disorder drug and considered the marketing application for the treatment to be premature. Sarepta shares fell 39 percent to $22.20

UK WINNERS & LOSERS: CRH Leads FTSE 100 Winners, John Menzies Dives

UPDATE 2-GlaxoSmithKline heart drug misses goal in major study

* Darapladib misses primary endpoint in Phase III trial * GSK says some success in secondary goals needs analysis * Expectations had been low for new type of heart medicine * Shares fall 1.2 percent By Ben Hirschler LONDON, Nov 12 (Reuters) - An experimental GlaxoSmi

BROKER RATING CHANGES: Goldman Cuts RBS To Neutral From Buy

Tuesday broker round-up UPDATE

Accesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation. Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review. Babcock International: Jefferies increases target price from 1250p to 1600p retaining a bu

GlaxoSmithKline Hit After Poor Study Results For Heart Disease Drug

London open: Stocks fall ahead of UK inflation data

- Markets eye inflation data - BoE Inflation Report due tomorrow - Corporate earnings come in mixed techMARK 2,636.87 -0.14% FTSE 100 6,706.83 -0.32% FTSE 250 15,395.24 -0.16% UK markets opened lower on Tuesday morning as investors refrained from building positions ahead of domestic inflation data

GlaxoSmithKline heart drug misses goal in major study

LONDON, Nov 12 (Reuters) - An experimental drug from GlaxoSmithKline, designed to fight heart disease in a new way, failed to meet its main goal in the first of two big late-stage clinical studies, the company said on Tuesday. Darapladib did, however, produce greater reductions in serious c

GlaxoSmithKline heart disease drug misses key target

GlaxoSmithKline's heart disease drug, darapladib, has missed a key milestone in its development. The trial drug, which is designed to tackle heart problems in a totally different way to cholesterol-lowering medication, was in the first of two "pivotal" late-stage clinical studies. Patrick Vallan

London pre-open: FTSE to open marginally higher

City sources predict the FTSE 100 will open around two points higher than yesterday's close of 6,728.37, tracking modest gains seen in the US last night and ahead of today's inflation figures. US markets ended slightly higher yesterday, with the Dow Jones Industrial Average hitting another record c

DIRECTOR DEALINGS: GlaxoSmithKline Executive Allocated ADSs

Crunch time for GlaxoSmithKline's big heart drug bet

* First Phase III trial data on darapladib due shortly * GSK sees once-daily pill as new way to fight heart disease * Analysts wary after lack of evidence in Phase II * Consensus forecasts point to $605 mln sales in 2018 * Billions of dollars upside if clinical trials succ

UPDATE 3-Novartis sells blood transfusion test unit to Grifols for $1.7 bln

* Divestment comes as Novartis reviews sub-scale operations * Acquisition to make diagnostics 20 pct of Grifols business * Deal expected to close in first half of 2014 * Grifols shares up 3.5 percent, Novartis adds 0.9 percent By Silke Koltrowitz and Sarah White ZURI

Ex-divs to take 11.6 points off FTSE 100 on Nov. 13

LONDON, Nov 11 (Reuters) - The following FTSE 100 companies will go ex-dividend on Wednesday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-

MARKET PULSE-Santarus, Sequenom, Durect, Tremor, Gap

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Nov 8 (Reuters) - U.S. stock index futures advanced on Friday, indicating the S&P 500 will r